Trending News

OCC Issues Bulletins on Customer Financial Record Protections and Politicized Debanking

Homebuyers Privacy Protection Act Signed Into Law, Restricting Trigger Leads

E-Verify Update: New Guidance for Employers on EAD Revocations

Responses to DOD Survey on Alternatives to TSCA High Priority Chemicals Due September 26, 2025

State Department Issues New, Immediate Requirement for Nonimmigrant Visa Applicants

Adjudicating Nonimmigrant Visa Applicants in Their Country of Residence — Implications for Employers and Employees

District Court Rejects First Amendment Challenge to California Climate Disclosure Requirements

This Week in 340B: August 5 – 11, 2025

DOL Resurrects PAID Program to Supervise Employers’ Self-Audits and Settlements of Potential FLSA and FMLA Violations

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
Posted On Monday, June 02, 2025
Elite Clinical Network Appoints Christopher Brennan as Chief Executive Officer
Posted On Monday, June 02, 2025
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
Posted On Monday, June 02, 2025
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
Posted On Monday, June 02, 2025
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
Posted On Monday, June 02, 2025
Liberation Labs is Now Liberation Bioindustries
Posted On Monday, June 02, 2025
PathAI and Northwestern Medicine Announce Strategic Collaboration to Deploy the AISight® Digital Pathology Platform and Co-Develop New AI Diagnostics
Posted On Monday, June 02, 2025
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
Posted On Monday, June 02, 2025
Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
Posted On Monday, June 02, 2025
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
Posted On Monday, June 02, 2025
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Posted On Monday, June 02, 2025
FDA expands XENOVIEW® indication to include children from six years of age
Posted On Monday, June 02, 2025
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
Posted On Monday, June 02, 2025
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
Posted On Monday, June 02, 2025
TELA Bio Appoints Jeffrey Blizard as President
Posted On Monday, June 02, 2025
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
Posted On Monday, June 02, 2025
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
Posted On Monday, June 02, 2025
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
Posted On Monday, June 02, 2025
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
Posted On Monday, June 02, 2025
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
Posted On Monday, June 02, 2025
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
Posted On Monday, June 02, 2025
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
Posted On Monday, June 02, 2025
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
Posted On Monday, June 02, 2025
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
Posted On Monday, June 02, 2025
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Posted On Sunday, June 01, 2025

Print